Puma Biotechnology Shares Plunge 14% Despite Q4 Beat on Weak 2026 Outlook

Puma Biotechnology (PBYI) reported strong fourth-quarter financial results that exceeded analyst expectations for both earnings and revenue. The biotechnology firm saw its revenue surge by 28% year-over-year during the quarter, driven by solid operational performance. However, these positive quarterly results were overshadowed by a disappointing financial forecast for the year 2026. Consequently, the company's stock price plummeted by 14% in after-hours trading as investors reacted to the weak long-term guidance. The market's reaction underscores a significant shift in focus toward future growth sustainability over immediate quarterly gains. Analysts noted that the downward revision in future expectations outweighed the current momentum in sales growth.